DK2976089T3 - Anvendelse af sedoheptulose til forebyggelse eller behandling af inflammation - Google Patents

Anvendelse af sedoheptulose til forebyggelse eller behandling af inflammation Download PDF

Info

Publication number
DK2976089T3
DK2976089T3 DK14711754.3T DK14711754T DK2976089T3 DK 2976089 T3 DK2976089 T3 DK 2976089T3 DK 14711754 T DK14711754 T DK 14711754T DK 2976089 T3 DK2976089 T3 DK 2976089T3
Authority
DK
Denmark
Prior art keywords
sedoheptulose
inflammation
prevention
treatment
Prior art date
Application number
DK14711754.3T
Other languages
English (en)
Inventor
Arvand Haschemi
Csörsz Nagy
Rodrig Marculescu
Oswald Wagner
Original Assignee
C7 Sugar Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by C7 Sugar Gmbh filed Critical C7 Sugar Gmbh
Application granted granted Critical
Publication of DK2976089T3 publication Critical patent/DK2976089T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004Monosaccharides having only carbon, hydrogen and oxygen atoms
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01NPRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00Preservation of bodies of humans or animals, or parts thereof
    • A01N1/02Preservation of living parts
    • A01N1/0205Chemical aspects
    • A01N1/021Preservation or perfusion media, liquids, solids or gases used in the preservation of cells, tissue, organs or bodily fluids
    • A01N1/0226Physiologically active agents, i.e. substances affecting physiological processes of cells and tissue to be preserved, e.g. anti-oxidants or nutrients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Dentistry (AREA)
  • Biophysics (AREA)
  • Environmental Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Physiology (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)
  • Psychology (AREA)
DK14711754.3T 2013-03-21 2014-03-21 Anvendelse af sedoheptulose til forebyggelse eller behandling af inflammation DK2976089T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13160443.1A EP2781219A1 (en) 2013-03-21 2013-03-21 Use of sedoheptulose for prevention or treatment of inflammation
PCT/EP2014/055679 WO2014147214A1 (en) 2013-03-21 2014-03-21 Use of sedoheptulose for prevention or treatment of inflammation

Publications (1)

Publication Number Publication Date
DK2976089T3 true DK2976089T3 (da) 2022-11-07

Family

ID=47901873

Family Applications (1)

Application Number Title Priority Date Filing Date
DK14711754.3T DK2976089T3 (da) 2013-03-21 2014-03-21 Anvendelse af sedoheptulose til forebyggelse eller behandling af inflammation

Country Status (16)

Country Link
US (2) US9694026B2 (da)
EP (2) EP2781219A1 (da)
JP (1) JP6388635B2 (da)
CN (2) CN115364112A (da)
AU (1) AU2014234230B2 (da)
BR (1) BR112015023463A2 (da)
CA (1) CA2903151C (da)
DK (1) DK2976089T3 (da)
ES (1) ES2930249T3 (da)
HU (1) HUE060237T2 (da)
MX (1) MX2015013378A (da)
NZ (1) NZ711523A (da)
PL (1) PL2976089T3 (da)
PT (1) PT2976089T (da)
WO (1) WO2014147214A1 (da)
ZA (1) ZA201506396B (da)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2781218A1 (en) 2013-03-21 2014-09-24 Medizinische Universität Wien Use of sedoheptulose as a nutritional supplement
CN106309458A (zh) * 2016-07-28 2017-01-11 中南大学湘雅医院 2‑脱氧‑d‑葡萄糖及其在药学上可接受的盐在制备治疗银屑病药物方面的应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3686022D1 (de) 1985-10-22 1992-08-20 Silvetti Sen Monosaccharide enthaltende zusammensetzung zum heilen von wunden.
JPH04335877A (ja) 1991-05-13 1992-11-24 Eimu:Kk 十薬食品・飲料並びに製造法
US9492582B2 (en) * 2000-11-08 2016-11-15 Fxs Ventures, Llc Ophthalmic and contact lens solutions containing simple saccharides as preservative enhancers
US20090252834A1 (en) 2004-05-10 2009-10-08 Michael Griffin Hayek Compositions comprising glucose anti-metabolites
ATE458409T1 (de) 2004-07-30 2010-03-15 Vb Medicare Pvt Ltd Süssstoffzusammensetzung mit reduziertem kaloriengehalt
WO2006093848A2 (en) 2005-02-28 2006-09-08 Mcneil Nutritionals, Llc Brown sugar substitute
JP5048238B2 (ja) * 2005-11-16 2012-10-17 エスエス製薬株式会社 ウワウルシ乾燥エキス含有経口製剤
GB0720516D0 (en) 2007-10-18 2007-11-28 Cadbury Schweppes Plc Comestible products
KR100912277B1 (ko) * 2007-11-21 2009-08-17 한국생명공학연구원 내열성 효소를 이용하여 세도헵툴로스를 제조하는 방법
CN101919872B (zh) * 2010-07-21 2011-12-07 广东粤龙药业有限公司 景酮糖酐在制备抗乙肝药物中的应用
GB201303698D0 (en) 2012-10-26 2013-04-17 Tate & Lyle Ingredients Sweetener syrups
CN103059071B (zh) * 2013-01-08 2016-03-16 华东理工大学 一种单糖的纳滤分离方法
EP2781218A1 (en) 2013-03-21 2014-09-24 Medizinische Universität Wien Use of sedoheptulose as a nutritional supplement

Also Published As

Publication number Publication date
AU2014234230B2 (en) 2018-08-09
US20170281661A1 (en) 2017-10-05
PL2976089T3 (pl) 2023-01-30
CN115364112A (zh) 2022-11-22
EP2976089B1 (en) 2022-08-17
NZ711523A (en) 2020-09-25
BR112015023463A2 (pt) 2017-07-18
EP2976089A1 (en) 2016-01-27
US20160045525A1 (en) 2016-02-18
CN105283188A (zh) 2016-01-27
WO2014147214A1 (en) 2014-09-25
CA2903151C (en) 2021-11-30
JP2016516077A (ja) 2016-06-02
HUE060237T2 (hu) 2023-02-28
ZA201506396B (en) 2018-05-30
ES2930249T3 (es) 2022-12-09
US10660910B2 (en) 2020-05-26
CA2903151A1 (en) 2014-09-25
EP2781219A1 (en) 2014-09-24
JP6388635B2 (ja) 2018-09-12
MX2015013378A (es) 2016-01-08
AU2014234230A1 (en) 2015-09-17
PT2976089T (pt) 2022-11-22
US9694026B2 (en) 2017-07-04

Similar Documents

Publication Publication Date Title
DK3334422T3 (da) Anvendelse af cannabidiolsyre i behandling af epilepsi
DK3206715T3 (da) Anvendelse af cannabidiol i behandling af tuberøs sklerosekompleks
DK3329909T3 (da) Fenfluramin til anvendelse i behandling af dravet syndrom
DK3033086T3 (da) Kombinationsterapi til behandling af cancer
DK3811943T3 (da) Forbindelse til anvendelse til behandling af øjenlidelser
DK2983787T3 (da) Fremgangsmåde til behandling af posttraumatisk stresssygdom
DK3185957T3 (da) Patisiran til anvendelse ved behandlingen af transthyretin-medieret amyloidosis
DK2968208T3 (da) Behandling af kataplexi
DK3481846T3 (da) 11-substituerede 24-hydroxysteroler til anvendelse til behandling af nmda-relaterede tilstande
DK3366307T3 (da) Sammensætninger og fremgangsmåder til inhibering af masp-1 og/eller masp-3 til behandling af paroxystisk nokturn hæmoglobinuri
DK3086793T3 (da) Anvendelse af oxygenerede cholesterolsulfater (ocs) til behandling af nyredysfunktion
DK2945642T3 (da) Faktor 1 protein til anvendelse i behandling eller forebyggelse af sygdomme
DK3374497T3 (da) Modificerede makrofager til anvendelse i behandlingen af kræft
DK3391902T5 (da) Plasminogen til anvendelse i behandlingen af diabetisk angiokardiopati
DK2991507T3 (da) Anvendelse af en sammensætning omfattende fiskeolie og juice til behandling og/eller efterbehandling af cancer
DK3204038T3 (da) Sammensætninger omfattende amylase til anvendelse i behandlingen af pruritus
DK2994157T3 (da) Tafa4-forbindelser og anvendelser deraf til behandling af smerte
DK3164123T3 (da) Hidtil ukendte anvendelser af benzylidenguanidinderivater til behandling af proteopatier
DK3052102T3 (da) Sammensætninger til behandling af cancere
DK3044229T3 (da) Peptider til anvendelse i behandlingen af oral mucositis
DK2984184T3 (da) Anvendelse af dnq eller dnq-87 i kombination med en parp1-inhibitor til behandlingen af cancer
DK2646039T3 (da) Sammensætning og anvendelse deraf i behandlingen af analrhagader
DK3071192T3 (da) Curcuphenolforbindelse til anvendelse i behandling af cancer
DK2964248T3 (da) Behandling af og profylakse for stråledermatitis
DK2976101T3 (da) Behandlingsfremgangsmåde